Short answer
Vertex Pharmaceuticals (VRTX) filed an 8-K current report with the SEC on May 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Board-approved 2026 Stock and Option Plan replacing the 2013 plan, subject to shareholder approval.
Vertex Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board-approved 2026 Stock and Option Plan replacing the 2013 plan, subject to shareholder approval
- Shareholders approved the new equity compensation plan on May 13, 2026
- Potential dilution and employee-retention implications through expanded or renewed stock-based compensation authority
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All 10 director nominees elected through 2027, with support ranging from 209.7M to 221.9M votes
- Ernst & Young LLP ratified as independent auditor for 2026, with 223.5M votes for and zero broker non-votes
- 2025 named-executive compensation program approved advisably, 207.9M votes for versus 14.5M against
- 2026 Stock and Option Plan approved, authorizing continued equity-based compensation
- Shareholder written-consent proposal passed, 126.9M votes for versus 95.8M against, potentially expanding shareholder action rights
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vertex Pharmaceuticals 8-K filings
Get the next VRTX 8-K as it lands
Follow VRTX for push alerts, or ask the research agent what this filing means.